Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance.
about
Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma linesMYC activation is a hallmark of cancer initiation and maintenanceNodal cytotoxic molecule (CM)-positive Epstein-Barr virus (EBV)-associated peripheral T cell lymphoma (PTCL): a clinicopathological study of 26 cases.Mechanisms that regulate Epstein-Barr virus EBNA-1 gene transcription during restricted latency are conserved among lymphocryptoviruses of Old World primates.Inactivation of MYC reverses tumorigenesis.The HLA system: structure and function.Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt's lymphoma cells.MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.The immunology of Epstein-Barr virus infectionBurkitt's lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology.Spontaneous regression of neoplasms: new possibilities for immunotherapy.Production of the immunosuppressive cytokine interleukin-10 by Epstein-Barr-virus-expressing pyothorax-associated lymphoma: possible role in the development of overt lymphoma in immunocompetent hostsTranscription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 proteinA simple reverse transcriptase PCR assay to distinguish EBNA1 gene transcripts associated with type I and II latency from those arising during induction of the viral lytic cycleIdentification of type B-specific and cross-reactive cytotoxic T-lymphocyte responses to Epstein-Barr virus.The Epstein-Barr virus EBNA-1 promoter Qp requires an initiator-like element.Interferon-independent and -induced regulation of Epstein-Barr virus EBNA-1 gene transcription in Burkitt lymphoma.Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine developmentIdentification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignanciesHost-cell-determined methylation of specific Epstein-Barr virus promoters regulates the choice between distinct viral latency programsImmune regulation in Epstein-Barr virus-associated diseasesThe Epstein-Barr virus nuclear protein 1 promoter active in type I latency is autoregulated.Epstein-Barr virus infection in carcinoma of the salivary glandHuman neonatal lymphocytes immortalized after microinjection of Epstein-Barr virus DNAA promoter for the highly spliced EBNA family of RNAs of Epstein-Barr virus.Immune escape by Epstein-Barr virus associated malignancies.Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.Acquisition of polyfunctionality by Epstein-Barr virus-specific CD8+ T cells correlates with increased resistance to galectin-1-mediated suppressionDifferentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity.The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules.Constitutive activation of Epstein-Barr virus (EBV) nuclear antigen 1 gene transcription by IRF1 and IRF2 during restricted EBV latency.Host cell and EBNA-2 regulation of Epstein-Barr virus latent-cycle promoter activity in B lymphocytes.Murine cytotoxic T lymphocytes recognize an epitope in an EBNA-1 fragment, but fail to lyse EBNA-1-expressing mouse cells.Enhanced tumorigenicity of an Epstein-Barr virus-transformed lymphoblastoid cell line is associated with a unique 1:18 chromosomal translocation and decreased expression of lymphocyte function associated antigen-1a (CD11A).Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide.Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance.Impaired long-term T cell immunity to Epstein-Barr virus in patients with nasopharyngeal carcinoma.Epstein-Barr virus-positive lymphoproliferative disorder associated with old organized chronic subdural hematoma.Primary central nervous system lymphoma in a child with acute B-cell lymphoblastic leukaemia: consecutive Epstein-Barr virus-related malignancies.
P2860
Q24605501-BEDAD1C4-E614-4921-AAB6-F3063B452352Q27026026-B84E5DFE-F165-44C3-BE85-8B40CCEB9C95Q33401775-0542062A-DBD0-40EC-8C9A-57EBE19ECC97Q33653017-16313A1E-9DB4-40C0-BA7A-9075672BCC0AQ33784668-A8400D9A-2BFF-4DAE-B537-7257F15A323CQ33838173-0798D8AD-CF48-4F84-B493-F21A64944D3DQ33880494-E791F61B-B37B-4DDC-A049-254880770158Q34048911-A0C65A95-8AB1-4F04-98D0-FCA1052E6A92Q34225567-90CB428C-338B-4A08-8C92-5EA7DC80BDDFQ34658852-24FFC512-225A-430F-B11F-DBA0D5013E2FQ34701352-1A49572F-4066-483F-8E75-5596465D01C5Q35765267-7AA7A873-FA81-4EAE-BA88-7B11F2C3F2ACQ35854017-C063E00F-6001-402F-B1B5-4E2709207AB0Q35872919-CDF31D38-097F-43C9-865A-0698A90E3A22Q35873998-87C776BB-1B8B-4468-8F50-91D1B1F27E91Q35874869-9C515FED-52FA-4651-AD71-E159979ED4A0Q35892261-4F268BED-4328-436D-972F-C4FADE33FF1BQ36231451-BEE6B6F3-02AA-4A7D-9E9E-0FBB658D82C6Q36231550-D5EDB202-D6F8-4C5B-8E1A-3CAA2B0195F7Q36564877-B7ABE8CC-7871-4579-9927-7BEA534FF0FEQ36669953-FF33C1A5-5E65-4DE9-AB4D-973588EA8E76Q36699468-07BEF53C-6BA3-4511-B03E-057455DD2898Q36829106-652CC56E-22DD-4C93-844D-BF587DD1E0BDQ36887656-16849AC7-3F96-41B7-B899-D2C2DE99EFEBQ36919542-E7CB4405-FD07-45EE-B19B-E6316B809666Q37041507-3AD991DC-B800-452A-8D25-FB9691E4E4D8Q37146126-FAF1E471-5268-43E5-AC90-5D541B27B2FCQ37204614-FAF21B3E-2C9F-4DC5-A127-9D5EEDB83E77Q37392755-4D73FA2B-B1F5-44AB-AD6C-35B3ED86BD16Q39753081-771FE847-5D08-4FAA-91B2-0119F55900C0Q40020928-A2BD9AB5-294B-4528-9D49-68FBA9234530Q40049217-F3CF40F9-C1EF-4B01-AF0F-EE11BAB210F9Q41059342-EBD6617B-6234-4EB2-8690-8ABA441918C1Q41535420-C03F2DCE-41D4-442B-B8DB-C17F57978F7AQ41780808-FD832B04-4C8F-48E8-9E30-8D8838F8ED68Q42818302-D249D5EC-95B3-4DFE-BDE2-117610394CCFQ44112947-19BAA1DA-7581-450B-8721-A6EC24EC0AB4Q45357499-23DD27DA-66CC-4F0B-85C4-635D92D3F45DQ45755796-AB45C1B5-A23E-4850-A171-F9414C322ABC
P2860
Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance.
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年学术文章
@wuu
1985年学术文章
@zh-cn
1985年学术文章
@zh-hans
1985年学术文章
@zh-my
1985年学术文章
@zh-sg
1985年學術文章
@yue
1985年學術文章
@zh
1985年學術文章
@zh-hant
name
Epstein-Barr virus-positive Bu ...... -specific T-cell surveillance.
@en
Epstein-Barr virus-positive Bu ...... -specific T-cell surveillance.
@nl
type
label
Epstein-Barr virus-positive Bu ...... -specific T-cell surveillance.
@en
Epstein-Barr virus-positive Bu ...... -specific T-cell surveillance.
@nl
prefLabel
Epstein-Barr virus-positive Bu ...... -specific T-cell surveillance.
@en
Epstein-Barr virus-positive Bu ...... -specific T-cell surveillance.
@nl
P2093
P921
P356
P1433
P1476
Epstein-Barr virus-positive Bu ...... -specific T-cell surveillance.
@en
P2093
Rickinson AB
Wallace LE
P2888
P304
P356
10.1038/317629A0
P407
P50
P577
1985-10-01T00:00:00Z
P6179
1047156875